Hutchison China MediTech Ltd.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment covers all activities related to oncology/immunology including sales, marketing, manufacturing and research and development with respect to drugs and drug candidates. The Other Ventures segment includes all other HUTCHMED businesses. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Hong Chen - Senior Vice President and Chief Commercial Officer, China Weiguo Su - Executive Director and Chief Scientific Officer Marek Kania - Executive Vice President, Managing Director and Chief Medical Officer, International Mark Lee - Senior Vice President, Corporate Finance & Development Johnny Cheng - Executive Director and Chief Financial Officer Karen Atkin - Executive Vice President and Chief Operating Officer Simon To - Chairman, Executive Director, Hutchison China Meditech Ltd. Conference Call Participants Kelly Shi - Jeffries Paul Choi - Goldman Sachs Mike Mitchell - Panmure Gordon Yang Huang - Credit Suisse Matthew Yan - CLSA Operator Dr. Marek Kania, our Managing Director and Chief Medical Officer of HUTCHMED International.

HUTCHMED (China) Limited (HCM) CEO Christian Hogg on Q2 2022 Results - Earnings Call Transcript

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE ® , SULANDA ® and ORPATHYS ® growth

HUTCHMED Reports 2022 Interim Results and Provides Business Updates

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient received their first dose on July 29, 2022.

HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

Hutchison China MediTech (HCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Hutchison China MediTech (HCM) Upgraded to Buy: What Does It Mean for the Stock?

— 49% ORR amongst SAVANNAH patients with higher MET levels — — 49% ORR amongst SAVANNAH patients with higher MET levels —

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody.

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August 1, 2022 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED to Announce 2022 Half-Year Financial Results

Los Angeles, California--(Newsfile Corp. - June 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HUTCHMED (China) Limited ("HUTCHMED" or "the Company") (NASDAQ: HCM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. HUTCHMED announced on May 2, 2022, that the FDA had rejected...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK® (tazemetostat) has been approved by the Health Commission and Medical Products Administration of Hainan Province to be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (“Hainan Pilot Zone”), under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma (“ES”) and follicular lymphoma (“FL”) consistent with the label as approved by the U.S. Food and Drug Administration (“FDA”). Launched in 2013 and located in China, the Hainan Pilot Zone is a destination for international medical tourism and global hub for scientific innovation, welcoming 83,900 medical tourists in 2020, according to official data.

HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

NEW YORK , May 30, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HUTCHMED (China) Limited ("Hutchmed" or the "Company") (NASDAQ: HCM). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HUTCHMED (China) Limited - HCM

New York, New York--(Newsfile Corp. - May 28, 2022) - Pomerantz LLP is investigating claims on behalf of investors of HUTCHMED (China) Limited ("Hutchmed" or the "Company") (NASDAQ: HCM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Hutchmed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

Shareholder Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Hutchmed (China) Limited - HCM

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of HUTCHMED (China) Limited (NASDAQ: HCM) resulting from allegations that HUTCHMED may have issued materially misleading business information to the investing public. SO WHAT: If you purchased HUTCHMED securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang

EQUITY ALERT: Rosen Law Firm Encourages HUTCHMED (China) Limited Investors with Losses to Inquire About Class Action Investigation – HCM

HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Alnylam Pharmaceuticals

Aptinyx Inc

Bristol-Myers

Blueprint Medicines

Coherus BioSciences

Tarsus Pharmaceuticals

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts.

7 Biotech Stocks to Buy With Key Catalysts for April

BeiGene

CASI Pharmaceuticals

Zai Lab Ltd.

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting stage, the framework from the China Securities Regulatory Commission and other national.

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

HONG KONG, and SHANGHAI, China and FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its status under the Holding Foreign Companies Accountable Act (the “Act”), following the Company's initial announcement on March 11, 2022.

Update on Status under Holding Foreign Companies Accountable Act

ACM Research

Alibaba

Baidu

Weibo

Yum China Hlds

Weibo Corp (WB), on Wednesday, joined previously identified Chinese stocks that may be delisted from U.S. exchanges. More could follow and Alibaba (BABA) could be in SEC crosshairs too.

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs

Shares of Chinese companies flagged for possible delisting in the U.S. slid in Hong Kong and Shanghai trading Friday, a move that analysts said highlighted geopolitical tensions but would have little immediate impact on the companies' operations.

Dow Jones Newswires: SEC-targeted Chinese companies slump; Yum China warns of 2024 delisting risk

Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way. The post Which Chinese Stocks Could Get Delisted?

Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.

Even China's most prominent companies were not immune to the sharp falls.

Why Chinese Stocks Are Falling Apart; Two Chinese Stocks to Dump Immediately

Li Auto Inc.

Tencent Music Entertainment Group 

Tesla

The risks of investing in Chinese stocks are growing.

Why Tesla Stock Slumped With Li Auto, Tencent Music, and Hutchmed

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM), have been flagged by the SEC for failing to comply with a law governing US-listed companies. In statements responding.

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today

Bilibili

iQIYI

JD.com

KraneShares CSI China Internet ETF

Pinduoduo Inc - ADR

Shares of many U.S.-listed Chinese stocks tumbled Thursday after the Securities and Exchange Commission put out an update about foreign companies using accounting firms or branches that cannot be adequately inspected.

MarketWatch: U.S.-listed China stocks sink as jitters build about overseas listings

A 2020 law called the Holding Foreign Companies Accountable Act may be behind the sharp decline in a handful of U.S-traded Chinese stocks.

News for Hutchison China MediTech Ltd. Stock (HCM)